To determine the role of HACE1 in glioma cells, we first designed two different siRNAs targeting HACE1 (siHACE1-1 and siHACE1–2), and validated their knockdown efficiency in U87 and SF295 cells (Fig. 2a). Here, HACE1 is linked to central nervous system cancer.